Register Login

AGIOS PHARMACEUTICALS, INC. (AGIO)

SymbolAGIO
NameAGIOS PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address88 SIDNEY STREET, CAMBRIDGE, Massachusetts, 02139, United States
Telephone+1 617 649-8600
Fax—
Email—
Websitehttps://www.agios.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001439222
Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The companys primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Additional info from NASDAQ:
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The companys primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

2026-07-21 11:00

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Read more
2026-07-02 20:03

Gheuens Sarah 🟡 adjusted position in 4.0K shares (1 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $37.56 Transaction Date: Jul 01, 2026 | Filing ID: 000110

Read more
2026-07-02 17:05

New Form SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001104659-26-080304 <b>Size:</b> 21 KB

Read more
2026-06-29 11:00

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Read more
2026-06-23 21:25

Director Ballal Rahul D. 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000107

Read more
2026-06-23 21:24

Director CAPELLO JEFFREY D 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000105

Read more
2026-06-23 21:23

Director Foster-Cheek Kaye I 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000103

Read more
2026-06-23 21:22

Director FOUSE JACQUALYN A 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000101

Read more
2026-06-23 21:21

Director Ho Maykin 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000099

Read more
2026-06-23 21:21

Director Owen Adams Catherine 🟡 adjusted position in 17.9K shares (3 derivative) of AGIOS PHARMACEUTICALS, INC. (AGIO) at $34.16 Transaction Date: Jun 18, 2026 | Filing ID: 000097

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT03245424 Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Muta… — Acute Myeloid Leukemia Approved_For_Marketing — — ClinicalTrials.gov
NCT07506863 A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat … Phase3 Transfusion-dependent Alpha-Thalassemia Not_Yet_Recruiting 2026-09-01 2032-06-01 ClinicalTrials.gov
NCT07517133 A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat … Phase3 Non-Transfusion-dependent Alpha-Thalassemia Not_Yet_Recruiting 2026-09-01 2032-03-01 ClinicalTrials.gov
NCT07656415 A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subject… Phase3 Sickle Cell Disease Not_Yet_Recruiting 2026-08-01 2030-08-01 ClinicalTrials.gov
NCT07241234 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… Phase1 Phenylketonuria Recruiting 2026-04-17 2028-01-17 ClinicalTrials.gov
NCT06286046 A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy Phase2 Sickle Cell Disease Withdrawn 2026-03-01 2028-12-01 ClinicalTrials.gov
NCT07075640 A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorb… Phase1 Healthy Participants Active_Not_Recruiting 2025-07-07 2026-08-31 ClinicalTrials.gov
NCT07055243 To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of t… Phase2 Anemia Recruiting 2025-06-26 2027-06-30 ClinicalTrials.gov
NCT06924970 A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participant… Phase2 Sickle Cell Disease Active_Not_Recruiting 2025-05-01 2027-05-01 ClinicalTrials.gov
NCT06745271 A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From t… Phase1 Healthy Participants Completed 2024-12-20 2025-02-21 ClinicalTrials.gov
NCT06648824 Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants Phase1 Healthy Participants Completed 2024-10-17 2024-12-03 ClinicalTrials.gov
NCT06286033 Single and Multiple Ascending Dose Study and Food Effect Study for AG181 Phase1 Healthy Volunteers Completed 2024-02-20 2025-10-09 ClinicalTrials.gov
NCT05777993 A Study to Provide Continued Access to Mitapivat for Participants Who Previousl… Phase4 Pyruvate Kinase Deficiency Enrolling_By_Invitation 2023-07-06 2029-08-01 ClinicalTrials.gov
NCT05610657 A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impa… Phase1 Moderate Hepatic Impairment Completed 2023-01-10 2023-07-21 ClinicalTrials.gov
NCT05490446 A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Mye… Phase2 Myelodysplastic Syndromes Active_Not_Recruiting 2022-11-07 2029-03-01 ClinicalTrials.gov
NCT05144256 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participa… Phase3 Pediatric Pyruvate Kinase Deficiency Active_Not_Recruiting 2022-06-08 2029-06-01 ClinicalTrials.gov
NCT05175105 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participa… Phase3 Pediatric Pyruvate Kinase Deficiency Active_Not_Recruiting 2022-06-06 2030-01-01 ClinicalTrials.gov
NCT05031780 A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participant… Phase2 Sickle Cell Disease Active_Not_Recruiting 2022-02-11 2030-02-01 ClinicalTrials.gov
NCT04902833 Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms — Pyruvate Kinase Deficiency Completed 2022-02-01 2026-02-01 ClinicalTrials.gov
NCT04770753 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With No… Phase3 Non-Transfusion-dependent Alpha-Thalassemia Active_Not_Recruiting 2021-12-20 2028-12-01 ClinicalTrials.gov
NCT04770779 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Tr… Phase3 Transfusion-dependent Alpha-Thalassemia Active_Not_Recruiting 2021-11-30 2029-06-01 ClinicalTrials.gov
NCT04056910 Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors Phase2 Advanced Solid Tumor Completed 2021-09-20 2023-11-13 ClinicalTrials.gov
NCT04995315 Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG… — Pyruvate Kinase Deficiency Completed 2021-07-02 2023-09-22 ClinicalTrials.gov
NCT04964323 Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported … — Pyruvate Kinase Deficiency Terminated 2021-07-02 2023-06-30 ClinicalTrials.gov
NCT04696393 A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet F… Phase1 Healthy Volunteers Completed 2021-01-06 2021-03-19 ClinicalTrials.gov
NCT04565678 A Study to Assess the Relative Bioavailability and Effect of Food on the Coated… Phase1 Healthy Volunteers Completed 2020-09-21 2020-12-03 ClinicalTrials.gov
NCT04536792 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… Phase1 Healthy Volunteers Completed 2020-07-10 2023-12-19 ClinicalTrials.gov
NCT04472832 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat… Phase1 Healthy Volunteers Completed 2020-06-17 2020-11-23 ClinicalTrials.gov
NCT04278781 AG-120 in People With IDH1 Mutant Chondrosarcoma Phase2 Chondrosarcoma Active_Not_Recruiting 2020-03-04 2027-03-01 ClinicalTrials.gov
NCT04145128 A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants Phase1 Healthy Volunteers Completed 2019-10-02 2019-12-18 ClinicalTrials.gov
NCT04128787 A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and … Phase1 Healthy Volunteers Completed 2019-09-30 2019-12-18 ClinicalTrials.gov
NCT04015687 A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Do… Phase1 Healthy Participants Completed 2019-07-15 2019-10-09 ClinicalTrials.gov
NCT04000165 A Dose-Finding Study of AG-348 in Sickle Cell Disease Early_Phase1 Sickle Cell Disease Completed 2019-07-11 2021-06-21 ClinicalTrials.gov
NCT03991312 Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on … Phase1 Healthy Volunteers Completed 2019-06-20 2019-09-10 ClinicalTrials.gov
NCT03834584 A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma Phase1 Lymphoma Terminated 2019-05-24 2020-06-17 ClinicalTrials.gov
NCT03960502 A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Follo… Phase1 Healthy Male Participants Completed 2019-05-16 2019-09-07 ClinicalTrials.gov
NCT03853798 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency… Phase3 Pyruvate Kinase Deficiency Completed 2019-03-21 2024-07-03 ClinicalTrials.gov
NCT03692052 A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynami… Phase2 Thalassemia Active_Not_Recruiting 2019-03-20 2030-09-30 ClinicalTrials.gov
NCT03564821 IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid… Phase1 IDH1 Mutation Myeloid Neoplasms Completed 2019-01-16 2023-06-06 ClinicalTrials.gov
NCT03548220 A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused A… Phase3 Pyruvate Kinase Deficiency Completed 2018-08-09 2020-10-09 ClinicalTrials.gov
NCT03559699 A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Ad… Phase3 Pyruvate Kinase Deficiency Completed 2018-06-26 2020-11-12 ClinicalTrials.gov
NCT03703505 A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Abs… Phase1 Healthy Volunteers Completed 2018-05-24 2018-06-04 ClinicalTrials.gov
NCT03481738 Pyruvate Kinase Deficiency Global Longitudinal Registry — Pyruvate Kinase Deficiency Active_Not_Recruiting 2018-04-23 2027-05-31 ClinicalTrials.gov
NCT03361358 Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma — Advanced Solid Tumors Completed 2018-03-01 2019-09-30 ClinicalTrials.gov
NCT03397329 Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet … Phase1 Healthy Volunteers Completed 2017-10-03 2017-11-13 ClinicalTrials.gov
NCT03282513 A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impair… Phase1 Hepatic Impairment Completed 2017-09-26 2018-03-31 ClinicalTrials.gov
NCT03250598 Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Hea… Phase1 Healthy Completed 2017-08-09 2017-10-09 ClinicalTrials.gov
NCT03071770 Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects Phase1 Healthy Completed 2017-03-31 2017-09-06 ClinicalTrials.gov
NCT02831972 Drug-Drug Interaction Study of AG120 in Healthy Subjects Phase1 Healthy Completed 2016-06-01 2016-10-01 ClinicalTrials.gov
NCT02630927 A Safety and Tolerability Study of AG-519 in Healthy Subjects Phase1 Anemia Terminated 2015-12-01 2016-12-01 ClinicalTrials.gov
NCT02579707 Food Effect Study of AG120 in Healthy Subjects Phase1 Healthy Completed 2015-10-01 2016-06-01 ClinicalTrials.gov
NCT02492737 Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malig… Phase1 Acute Myeloid Leukemia (AML) Completed 2015-08-07 2018-03-21 ClinicalTrials.gov
NCT02476916 A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency Phase2 Pyruvate Kinase Deficiency Completed 2015-06-26 2025-04-02 ClinicalTrials.gov
NCT02489513 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 Phase1 Healthy Volunteers Completed 2015-06-01 2015-10-01 ClinicalTrials.gov
NCT02218346 Food Effect Study of AG-221 in Healthy Male Subjects Phase1 Healthy Volunteers Completed 2014-08-01 2015-03-01 ClinicalTrials.gov
NCT02149966 A Phase I Study of AG-348 in Healthy Volunteers Phase1 Healthy Volunteer Completed 2014-05-01 2014-11-01 ClinicalTrials.gov
NCT02108106 A Phase I Study of AG-348 in Healthy Volunteers Phase1 Healthy Volunteer Completed 2014-03-01 2014-08-01 ClinicalTrials.gov
NCT01915498 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Mali… Phase1 Hematologic Neoplasms Completed 2013-08-27 2023-10-31 ClinicalTrials.gov
Total clinical trials: 58
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07506863
Mitapivat Matched Placebo Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07506863
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat Other Phase PHASE4 Pyruvate Kinase Deficiency ENROLLING_BY_INVITATION NCT05777993
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE3 Sickle Cell Disease NOT_YET_RECRUITING NCT07656415
Mitapivat Matched Placebo Other Phase PHASE3 Sickle Cell Disease NOT_YET_RECRUITING NCT07656415
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Sickle Cell Disease NOT_YET_RECRUITING NCT07656415
Mitapivat Matched Placebo Other Phase PHASE3 Sickle Cell Disease NOT_YET_RECRUITING NCT07656415
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07506863
Mitapivat Matched Placebo Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07506863
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Blood Draw Other Preclinical Pyruvate Kinase Deficiency COMPLETED NCT04902833
Placebo Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02149966
AG-348 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02149966
AG-348 Sequence B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03397329
AG-348 Sequence A Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03397329
Placebo Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02108106
AG-348 Other Phase PHASE1 Healthy Volunteer COMPLETED NCT02108106
[14C]-AG-120 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02489513
AG221 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02218346
AG120 Other Phase PHASE1 Healthy COMPLETED NCT02579707
Itraconazole Other Phase PHASE1 Healthy COMPLETED NCT02831972
AG120 Other Phase PHASE1 Healthy COMPLETED NCT02831972
Placebo Other Phase PHASE1 Anemia TERMINATED NCT02630927
AG-519 Other Phase PHASE1 Anemia TERMINATED NCT02630927
AG-348 Other Phase PHASE1 Healthy COMPLETED NCT03250598
ivosidenib (AG-120) Other Phase PHASE1 Healthy COMPLETED NCT03071770
AG-120 (Ivosidenib) Other Phase PHASE1 Hepatic Impairment COMPLETED NCT03282513
ivosidenib (AG-120) Other Preclinical Acute Myeloid Leukemia APPROVED_FOR_MARKETING NCT03245424
[13C6]AG-348 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03703505
AG-348 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03703505
AG881 Other Phase PHASE1 Acute Myeloid Leukemia (AML) COMPLETED NCT02492737
Lamotrigine Other Phase PHASE1 Healthy Participants COMPLETED NCT04015687
AG-881 Other Phase PHASE1 Healthy Participants COMPLETED NCT04015687
mitapivat sulfate Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
rifampin Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
itraconazole Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
[13C315N3]AG-881 Other Phase PHASE1 Healthy Male Participants COMPLETED NCT03960502
AG-881 Other Phase PHASE1 Healthy Male Participants COMPLETED NCT03960502
AG881 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04145128
AG-636 Other Phase PHASE1 Lymphoma TERMINATED NCT03834584
Mitapivat coated granules Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04565678
Mitapivat tablets Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04565678
Placebo for Treatment C Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Mitapivat 300 mg Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Placebo for Treatment B Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Mitapivat 100 mg Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Placebo for Treatment A Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Mitapivat tablet Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04696393
Omeprazole Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04128787
AG881 Formulation 2 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04128787
AG881 Formulation 1 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04128787
AG-348 Other Phase PHASE3 Pyruvate Kinase Deficiency COMPLETED NCT03559699
AG-348 Other Phase PHASE3 Pyruvate Kinase Deficiency COMPLETED NCT03548220
Placebo Other Phase PHASE3 Pyruvate Kinase Deficiency COMPLETED NCT03548220
AG-348 Other Phase EARLY_PHASE1 Sickle Cell Disease COMPLETED NCT04000165
Mitapivat Other Phase PHASE1 Moderate Hepatic Impairment COMPLETED NCT05610657
AG-946 Matched Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04536792
AG-946 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04536792
Enasidenib Other Phase PHASE1 Hematologic Neoplasms COMPLETED NCT01915498
Midazolam Other Phase PHASE1 Healthy Participants COMPLETED NCT06648824
Mitapivat Other Phase PHASE1 Healthy Participants COMPLETED NCT06648824
ivosidenib and nivolumab Other Phase PHASE2 Advanced Solid Tumor COMPLETED NCT04056910
[13C2,15N3]-tebapivat Other Phase PHASE1 Healthy Participants COMPLETED NCT06745271
[14C]-tebapivat Other Phase PHASE1 Healthy Participants COMPLETED NCT06745271
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
Mitapivat Other Phase PHASE2 Anemia RECRUITING NCT07055243
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Ivosidenib Other Phase PHASE1 IDH1 Mutation Myeloid Neoplasms COMPLETED NCT03564821
Mitapivat Other Phase PHASE3 Pyruvate Kinase Deficiency COMPLETED NCT03853798
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06286033
AG-181 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06286033
Blood Draw Other Preclinical Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT04902833
Mitapivat Other Phase PHASE4 Pyruvate Kinase Deficiency ENROLLING_BY_INVITATION NCT05777993
AG-348 Other Phase PHASE2 Thalassemia ACTIVE_NOT_RECRUITING NCT03692052
Mitapivat Other Phase PHASE2 Sickle Cell Disease WITHDRAWN NCT06286046
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
AG-348 Other Phase PHASE2 Pyruvate Kinase Deficiency COMPLETED NCT02476916
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Placebo Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
AG-236 Other Phase PHASE1 Healthy Participants ACTIVE_NOT_RECRUITING NCT07075640
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Placebo Matching Mitapivat Other Phase PHASE3 Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770779
Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Placebo Matching Mitapivat Other Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ACTIVE_NOT_RECRUITING NCT04770753
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05144256
AG-181 Other Phase PHASE1 Phenylketonuria RECRUITING NCT07241234
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Other Phase PHASE2 Myelodysplastic Syndromes ACTIVE_NOT_RECRUITING NCT05490446
Mitapivat-matching placebo Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Mitapivat Other Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
AG-120 Other Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Mitapivat-matching placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Mitapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT05031780
Tebapivat Matched Placebo Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Tebapivat Other Phase PHASE2 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT06924970
Placebo and AIR001 Inhalation Solution (Expansion arm) DRUG Phase PHASE1 Pulmonary Arterial Hypertension COMPLETED NCT00814645
25% MTD sodium nitrite inhalation solution DRUG Phase PHASE1 Pulmonary Hypertension COMPLETED NCT01409122
120 mg sodium nitrite inhalation solution DRUG Phase PHASE1 Pulmonary Hypertension COMPLETED NCT01409122
45 mg sodium nitrite inhalation solution DRUG Phase PHASE1 Pulmonary Hypertension COMPLETED NCT01409122
90 mg sodium nitrite inhalation solution DRUG Phase PHASE1 Pulmonary Hypertension COMPLETED NCT01409122
15 mg sodium nitrite inhalation solution DRUG Phase PHASE1 Pulmonary Hypertension COMPLETED NCT01409122
Ezetimibe DRUG Phase PHASE2 Hypercholesterolemia COMPLETED NCT00405067
BMS-201038 (AEGR-733) DRUG Phase PHASE2 Hypercholesterolemia COMPLETED NCT00405067
Gemfibrozil DRUG Phase PHASE1 Healthy COMPLETED NCT02230033
JNJ-56021927 tablet DRUG Phase PHASE1 Healthy COMPLETED NCT02031666
JNJ-56021927 capsule DRUG Phase PHASE1 Healthy COMPLETED NCT02031666
Sodium Nitrite Inhalation Solution DRUG Phase PHASE1 Pulmonary Arterial Hypertension COMPLETED NCT00814645
Lomitapide DRUG Phase PHASE2 Homozygous Familial Hypercholesterolemia COMPLETED NCT01556906
AEGR-733 and ezetimibe DRUG Phase PHASE2 Hyperlipidemia COMPLETED NCT00559962
AEGR-733 and fenofibrate DRUG Phase PHASE2 Hyperlipidemia COMPLETED NCT00559962
AEGR-733 and atorvastatin DRUG Phase PHASE2 Hyperlipidemia COMPLETED NCT00559962
placebo DRUG Phase PHASE2 Hyperlipidemia COMPLETED NCT00559962
AEGR-733 DRUG Phase PHASE2 Hypercholesterolemia COMPLETED NCT00690443
Extended Release Niacin DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
dextromethorphan DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
fenofibrate DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
ezetimibe DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
simvastatin DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
atorvastatin DRUG Phase PHASE2 Healthy COMPLETED NCT00359281
EE/norgestimate DRUG Phase PHASE1 Healthy COMPLETED NCT02080468
Nebulized Sodium Nitrite DRUG Phase PHASE2 Heart Failure COMPLETED NCT02742129
RAD1901 DRUG Phase PHASE2 Hot Flashes COMPLETED NCT00875420
[14]-AST2818 DRUG Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03941340
AST2818 Tablets DRUG Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03926182
Atorvastatin DRUG Phase PHASE2 Hypercholesterolemia COMPLETED NCT00690443
lomitapide DRUG Phase PHASE1 Healthy COMPLETED NCT02044419
LHRH Agonist DRUG Phase PHASE2 Prostate Cancer COMPLETED NCT01790126
Furmonertinib (160mg) DRUG Phase PHASE2 Non-Small-Cell Lung Cancer UNKNOWN NCT05255406
RAD011 DRUG Phase PHASE3 Prader-Willi Syndrome WITHDRAWN NCT05387798
Anlotinib DRUG Phase PHASE2 Non-Small-Cell Lung Cancer UNKNOWN NCT04895930
JNJ-56021927 Tablet Formulation 3 DRUG Phase PHASE1 Healthy COMPLETED NCT02160756
JNJ-56021927 Tablet Formulation 2 DRUG Phase PHASE1 Healthy COMPLETED NCT02160756
JNJ-56021927 Tablet Formulation 1 DRUG Phase PHASE1 Healthy COMPLETED NCT02160756
JNJ-56021927 Softgel Capsule DRUG Phase PHASE1 Healthy COMPLETED NCT02160756
ARN-509 DRUG Phase PHASE2 Prostate Cancer COMPLETED NCT01790126
Alflutinib DRUG Phase PHASE2 Advanced NSCLC Patients With T790M TERMINATED NCT03452592
Carboplatin DRUG Phase PHASE3 Advanced Non-squamous Non-small-cell Lung Cancer RECRUITING NCT06416410
Pemetrexed DRUG Phase PHASE3 Advanced Non-squamous Non-small-cell Lung Cancer RECRUITING NCT06416410
Tislelizumab DRUG Phase PHASE3 Advanced Non-squamous Non-small-cell Lung Cancer RECRUITING NCT06416410
Rifampicin DRUG Phase PHASE1 Healthy Subjects COMPLETED NCT06162169
Midazolam , Rosuvastatin calcium and digoxin DRUG Phase PHASE1 Healthy Subjects COMPLETED NCT06162169
[14C]JAB-21822 DRUG Phase PHASE1 Mass Balance Study in Healthy Subjects COMPLETED NCT05920941
Osimertinib DRUG Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Sotorasib DRUG Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Pembrolizumab DRUG Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Binimetinib DRUG Phase PHASE1 Solid Tumor COMPLETED NCT04720976
Placebo AST2818 80mg//40 mg DRUG Phase PHASE3 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT03787992
Gefitinib 250 mg DRUG Phase PHASE3 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT03787992
Placebo Gefitinib 250 mg DRUG Phase PHASE3 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT03787992
Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo DRUG Phase PHASE3 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING NCT03787992
[18F]RP-115 PET/MRI or PET/CT and MRI DRUG Phase PHASE1 Alzheimer Disease RECRUITING NCT05374278
JAB-3312 DRUG Phase PHASE3 Advanced Non-squamous Non-small-cell Lung Cancer RECRUITING NCT06416410
Furmonertinib DRUG Phase PHASE2 Lung Adenocarcinoma NOT_YET_RECRUITING NCT04965831
Furmonertinib 240mg DRUG Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT04858958
Furmonertinib 160mg DRUG Phase PHASE1 NSCLC ACTIVE_NOT_RECRUITING NCT04858958
Metreleptin DRUG Phase PHASE4 Generalized Lipodystrophy COMPLETED NCT04026178
ADT (Standard of Care) DRUG Preclinical Prostatic Neoplasms NO_LONGER_AVAILABLE NCT03523338
ASTX727 DRUG Phase PHASE2 Malignant Peripheral Nerve Sheath Tumors (MPNST) RECRUITING NCT04872543
Osimertinib Mesylate Tablets DRUG Phase PHASE3 NSCLC Patients With Brain Metastasis RECRUITING NCT06970639
Furmonertinib Mesilate Tablets DRUG Phase PHASE3 NSCLC Patients With Brain Metastasis RECRUITING NCT06970639
Carboplatin Injection DRUG Phase PHASE3 NSCLC Patients With Brain Metastasis RECRUITING NCT06970639
Cisplatin for injection DRUG Phase PHASE3 NSCLC Patients With Brain Metastasis RECRUITING NCT06970639
Pemetrexed Disodium for Injection DRUG Phase PHASE3 NSCLC Patients With Brain Metastasis RECRUITING NCT06970639
Firmonertinib Mesilate Tablets DRUG Phase PHASE3 EGFR RECRUITING NCT06956001
AST2303 Tablets(ABK3376 Tablets) ，125mg DRUG Phase PHASE1 Locally Advanced or Metastatic Non-small Cell Lung Cancer RECRUITING NCT06955988
AST2303 Tablets(ABK3376 Tablets) ，100mg DRUG Phase PHASE1 Locally Advanced or Metastatic Non-small Cell Lung Cancer RECRUITING NCT06955988
AST2303 Tablets(ABK3376 Tablets) ，75mg DRUG Phase PHASE1 Locally Advanced or Metastatic Non-small Cell Lung Cancer RECRUITING NCT06955988
AST2303 Tablets(ABK3376 Tablets) ，50mg DRUG Phase PHASE1 Locally Advanced or Metastatic Non-small Cell Lung Cancer RECRUITING NCT06955988
AST2303 Tablets(ABK3376 Tablets) ，25mg DRUG Phase PHASE1 Locally Advanced or Metastatic Non-small Cell Lung Cancer RECRUITING NCT06955988
ARN-509 (Phase 2) DRUG Phase PHASE1 Prostate Cancer COMPLETED NCT01171898
ARN-509 (Phase 1) DRUG Phase PHASE1 Prostate Cancer COMPLETED NCT01171898
Rosuvastatin DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ACTIVE_NOT_RECRUITING NCT02592317
Pioglitazone DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ACTIVE_NOT_RECRUITING NCT02592317
Drug Cocktail DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ACTIVE_NOT_RECRUITING NCT02592317
JNJ 56021927 DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ACTIVE_NOT_RECRUITING NCT02592317
JNJ-56021927 DRUG Phase PHASE1 Healthy COMPLETED NCT02230033
Abiraterone Acetate DRUG Phase PHASE1 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02123758
Cetuximab DRUG Phase PHASE1 Advanced Colorectal Cancer ACTIVE_NOT_RECRUITING NCT05194995
JAB-21822 DRUG Phase PHASE3 Advanced Non-squamous Non-small-cell Lung Cancer RECRUITING NCT06416410
Fusidic Acid 1% DRUG Phase PHASE3 Bacterial Conjunctivitis RECRUITING NCT06911424
74-80 Grays (units of radiation) RADIATION Phase PHASE3 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02531516
GnRH (agonist) DRUG Phase PHASE3 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02531516
Apalutamide Placebo DRUG Phase PHASE3 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02531516
Bicalutamide Placebo DRUG Phase PHASE3 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02531516
Bicalutamide DRUG Phase PHASE3 Prostatic Neoplasms ACTIVE_NOT_RECRUITING NCT02531516
Androgen Deprivation Therapy (ADT) DRUG Phase PHASE3 Prostate Cancer ACTIVE_NOT_RECRUITING NCT02489318
Prednisone DRUG Phase PHASE1 Prostate Cancer COMPLETED NCT01792687
Abiraterone acetate DRUG Phase PHASE1 Prostate Cancer COMPLETED NCT01792687
Apalutamide DRUG Phase PHASE1 Castration-Resistant Prostate Cancer COMPLETED NCT02578797
Mitapivat Matched Placebo DRUG Phase PHASE3 Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07506863
AG-236 DRUG Phase PHASE1 Healthy Participants RECRUITING NCT07075640
Tebapivat Matched Placebo DRUG Phase PHASE2 Sickle Cell Disease RECRUITING NCT06924970
[13C2,15N3]-tebapivat DRUG Phase PHASE1 Healthy Participants COMPLETED NCT06745271
[14C]-tebapivat DRUG Phase PHASE1 Healthy Participants COMPLETED NCT06745271
Midazolam DRUG Phase PHASE1 Healthy Participants COMPLETED NCT06648824
AG-181 DRUG Phase PHASE1 Phenylketonuria NOT_YET_RECRUITING NCT07241234
Tebapivat DRUG Phase PHASE2 Sickle Cell Disease RECRUITING NCT06924970
Mitapivat-matching placebo DRUG Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT05175105
Blood Draw PROCEDURE Preclinical Pyruvate Kinase Deficiency ACTIVE_NOT_RECRUITING NCT04902833
Placebo Matching Mitapivat DRUG Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
Mitapivat tablet DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04696393
Mitapivat coated granules DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04565678
Mitapivat tablets DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04565678
AG-946 Matched Placebo DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04536792
AG-946 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04536792
Placebo for Treatment C DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Mitapivat 300 mg DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Placebo for Treatment B DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Mitapivat 100 mg DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
Placebo for Treatment A DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04472832
AG-120 DRUG Phase PHASE2 Chondrosarcoma ACTIVE_NOT_RECRUITING NCT04278781
Omeprazole DRUG Phase PHASE1 Healthy Subjects COMPLETED NCT06162169
AG881 Formulation 2 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04128787
AG881 Formulation 1 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04128787
ivosidenib and nivolumab DRUG Phase PHASE2 Advanced Solid Tumor COMPLETED NCT04056910
Lamotrigine DRUG Phase PHASE1 Healthy Participants COMPLETED NCT04015687
mitapivat sulfate DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
rifampin DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
itraconazole DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03991312
[13C315N3]AG-881 DRUG Phase PHASE1 Healthy Male Participants COMPLETED NCT03960502
AG-881 DRUG Phase PHASE1 Healthy Participants COMPLETED NCT04015687
Mitapivat DRUG Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia NOT_YET_RECRUITING NCT07517133
AG-636 DRUG Phase PHASE1 Lymphoma TERMINATED NCT03834584
[13C6]AG-348 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03703505
Ivosidenib DRUG Phase PHASE1 IDH1 Mutation Myeloid Neoplasms COMPLETED NCT03564821
AG-348 Sequence B DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03397329
AG-348 Sequence A DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03397329
AG-120 (Ivosidenib) DRUG Phase PHASE1 Hepatic Impairment COMPLETED NCT03282513
ivosidenib (AG-120) DRUG Preclinical Acute Myeloid Leukemia APPROVED_FOR_MARKETING NCT03245424
Itraconazole DRUG Phase PHASE1 Healthy COMPLETED NCT02230033
AG-519 DRUG Phase PHASE1 Anemia TERMINATED NCT02630927
AG120 DRUG Phase PHASE1 Healthy COMPLETED NCT02831972
AG881 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04145128
[14C]-AG-120 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02489513
AG221 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02218346
Placebo OTHER Phase PHASE2 Heart Failure COMPLETED NCT02262078
AG-348 DRUG Phase EARLY_PHASE1 Sickle Cell Disease COMPLETED NCT04000165
Enasidenib DRUG Phase PHASE1 Hematologic Neoplasms COMPLETED NCT01915498
Total products: 492